Jump to main content
Jump to site search

Issue 7, 2014
Previous Article Next Article

KRAS NF-κB is involved in the development of zinc resistance and reduced curability in prostate cancer

Author affiliations

Abstract

Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, the expression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1α, KRAS, mTOR, MT1A, MT2A, NF-κB1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher. With regard to the gene expression profiles, our results indicate that differential mechanisms participate in the short-term zinc toxicity regulation and long-term resistance; the short-term treatment was associated with MT2A (p < 0.001), ZnT-1 (p < 0.001), and MT1A (p < 0.03) and the long-term resistance was associated particularly with NF-κB1 (p < 0.001), CFLAR (p < 0.001), KRAS (p < 0.001), p53 (p < 0.002), survivin (p = 0.02), ZIP1 (p = 0.002), BAX (p = 0.005), and HIF1α (p = 0.05). Therefore, the KRAS-PI3K-NF-κB pathway is expected to play a crucial role in the regulation of zinc resistance. In summary, compared to previous studies, identical mechanisms of resistance were demonstrated on multiple cell lines, both non-tumor and tumorous, derived both from primary and advanced secondary sites.

Graphical abstract: KRAS NF-κB is involved in the development of zinc resistance and reduced curability in prostate cancer

Back to tab navigation

Publication details

The article was received on 28 Feb 2014, accepted on 06 May 2014 and first published on 06 May 2014


Article type: Paper
DOI: 10.1039/C4MT00065J
Metallomics, 2014,6, 1240-1253

  •   Request permissions

    KRAS NF-κB is involved in the development of zinc resistance and reduced curability in prostate cancer

    M. Holubova, M. Axmanova, J. Gumulec, M. Raudenska, M. Sztalmachova, P. Babula, V. Adam, R. Kizek and M. Masarik, Metallomics, 2014, 6, 1240
    DOI: 10.1039/C4MT00065J

Search articles by author

Spotlight

Advertisements